As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on April 13, 2022, by Antares Pharma, Inc. (Company), the Company entered into an Agreement and Plan of Merger, dated April 12, 2022, with Halozyme Therapeutics, Inc. (Halozyme), and Atlas Merger Sub, Inc. and a wholly owned subsidiary of Halozyme (Purchaser). Pursuant to the Merger Agreement, effective as of the Effective Time, Leonard S. Jacob, M.D., Ph.D., Thomas J. Garrity, Peter S. Greenleaf, Anton Gueth, Robert P. Roche Jr., Karen Smith, M.D., Ph.D., Carmen B. Volkart, and Robert F. Apple each ceased to be directors of the Company and members of any committee of the Company's board of directors. These departures were not a result of any disagreement between the Company and the directors on any matter relating to the Company's operations, policies or practices.

Pursuant to the Merger Agreement, effective as of the Effective Time, Robert F. Apple, Fred M. Powell, Peter J. Graham, Esq. and Peter C. Richardson, M.D. each ceased to be officers of the Company. Further, pursuant to the Merger Agreement and effective immediately after the Effective Time, each of Helen Torley, M.B. Ch.B., M.R.C.P., and Nicole LaBrosse became the officers and directors of the Surviving Corporation.

Information regarding the new directors and officers of the Surviving Corporation has been previously disclosed in the Tender Offer Statement on Schedule TO filed by Halozyme and Purchaser with the SEC on April 26, 2022 (together with the exhibits and annexes thereto and as amended or supplemented from time to time), which is incorporated herein by reference.